Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PeptiDreamPPTDF 81 Cash-to-Debt is 1.51 as of Jun. 2026, which is 100% below its 10-year median of 10,000.00. GuruFocus rates PPTDF with a GF Score™ of 81/100 and a GF Value™ of $6.04 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 1,398 Biotechnology companies, PeptiDream ranks worse than 71.89% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. PeptiDream's cash to debt ratio for the quarter that ended in Jun. 2026 was 1.51.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, PeptiDreamcould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for PeptiDream's Cash-to-Debt or its related term are showing as below:
PPTDF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.24 Med: No Debt Max: No Debt
Current: 1.51
During the past 13 years, PeptiDream's highest Cash to Debt Ratio was No Debt. The lowest was 0.24. And the median was No Debt.
PPTDF's Cash-to-Debt is ranked worse than 71.89% of 1398
companies
in the Biotechnology industry
Industry Median: 6.68
vs PPTDF: 1.51
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
PeptiDream Cash-to-Debt Related Terms
PeptiDream Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for PeptiDream's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
PPTDF vs VRTX, REGN, MRNA: Cash-to-Debt Comparison
For the Biotechnology subindustry, PeptiDream's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PeptiDream Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PeptiDream's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where PeptiDream's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PeptiDream (PPTDF) has a Cash-to-Debt of 1.51 as of Jun. 2026. This is 100% below median its historical median of 10,000.00. Over the past decade, PeptiDream's Cash-to-Debt has ranged from 0.24 to 10,000.00. According to the industry distribution chart, PeptiDream ranks #1005 out of 1398 companies in the Biotechnology industry, placing it in the top 71.9%.
Is PeptiDream's Cash-to-Debt too high?
PeptiDream's current Cash-to-Debt of 1.51 is 100% below median its 10-year median of 10,000.00. Over the past 10 years, this metric has ranged from a low of 0.24 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 6.68. PeptiDream's value of 1.51 is 77.4% below this industry median. Based on the distribution chart, PeptiDream ranks #1005 out of 1398 companies in the Biotechnology industry, which is below the industry midpoint. Overall, PeptiDream has a GF Score™ of 81/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PeptiDream's Cash-to-Debt compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PeptiDream ranks #1005 out of 1398 companies for Cash-to-Debt. This places PeptiDream in the lower half of its industry. The industry median Cash-to-Debt is 6.68. PeptiDream's value of 1.51 is 77.4% below this benchmark. Historically, PeptiDream's own Cash-to-Debt has ranged from 0.24 to 10,000.00 over the past decade. While the company's 10-year median is 10,000.00 vs. the industry median of 6.68, PeptiDream has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.68, based on 1,398 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PeptiDream's current Cash-to-Debt of 1.51 is 77.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PeptiDream's current Cash-to-Debt is 1.51, which is 100% below median its own 10-year median of 10,000.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PeptiDream stock overvalued right now?
Based on GuruFocus' analysis, PeptiDream (PPTDF) is currently considered Modestly Overvalued. The stock's GF Value™ is $6.04, compared to a current price of $7.00 — trading 15.9% above its estimated fair value. The current Cash-to-Debt is 1.51, which is 100% below median its 10-year median of 10,000.00 and 77.4% below the Biotechnology industry median of 6.68. PeptiDream's overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For PeptiDream (PPTDF), the current Cash-to-Debt is 1.51 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PeptiDream (PPTDF) Overvalued in 2026?
Based on GuruFocus' analysis, PeptiDream stock appears to be overvalued.
The current stock price of $7.00 is trading 15.9% above its estimated GF Value™ of $6.04.
GuruFocus considers PeptiDream to be Modestly Overvalued.
Key valuation signals for PPTDF:
Cash-to-Debt: 1.51 (100% below median its 10-year median of 10,000.00)
GF Value™: $6.04 vs. price of $7.00 (15.9% above fair value)
Industry Position: 77.4% below the Biotechnology median (#1005 of 1398)
No single metric tells the full story. See the PPTDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PeptiDream Inc is engaged in the drug discovery and development business. The group utilizes PDPS, its proprietary drug discovery and development platform system, for drug discovery and development, and it conducts radiopharmaceutical business through a wholly owned subsidiary and is involved in the research, development, and manufacturing of pharmaceuticals, etc. Its reportable segments are Drug discovery and development business and Radiopharmaceutical business.
81GF Score
Get the complete analysis for PPTDF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PPTDF has been successfully added to your 
